pharma · B-cell Acute Lymphoblastic Leukemia
Zhujiang Hospital
Zhujiang Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include B-cell Acute Lymphoblastic Leukemia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent rec
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
CD19 CAR T-Cell(CAT19T2)
Phase 2 · mab · B-cell Acute Lymphoblastic Leukemia
CD19 CAR T-Cell(CAT19T2) for B-cell Acute Lymphoblastic Leukemia is a Phase 2 program (mab) at Zhujiang Hospital with 1 ClinicalTrials.gov record(s).
Internal code 2022-KY-094
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zhujiang Hospital
- Phase
- Phase 2
- Modality
- mab
- Indication
- B-cell Acute Lymphoblastic Leukemia
- Status
- terminated
- Trials
- 1